Regorafenib in the treatment of malignant tumor / 国际肿瘤学杂志
Journal of International Oncology
; (12): 191-192,231, 2013.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-598211
Responsible library:
WPRO
ABSTRACT
Regorafenib,an oral multi-kinase inhibitor,can inhabit a class of receptor tyrosine kinase,such as angiogenic,stromal,oncogenic and so on.Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity.The results of clinical trials are encouraging for the treatment of Refractory solid tumors,especially for colorectal carcinoma.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2013
Document type:
Article